223673-61-8 | 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$48.00	$34.00
25mg	97%	in stock	$103.00	$73.00
250mg	97%	in stock	$106.00	$74.00
1g	97%	in stock	$155.00	$108.00
5g	97%	in stock	$473.00	$331.00
10g	97%	in stock	$791.00	$554.00
25g	97%	in stock	$1,536.00	$1,075.00

Description

• Catalog Number: AB49878
• Chemical Name: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
• CAS Number: 223673-61-8
• Molecular Formula: C21H24N4O2S
• Molecular Weight: 396.5059
• MDL Number: MFCD11100356
• SMILES: O=C(Cc1csc(n1)N)Nc1ccc(cc1)CCNC[C@@H](c1ccccc1)O

Computed Properties

• Complexity: 467
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 9
• XLogP3: 2.1

Literature

• Mirabegron: potential off target effects and uses beyond the bladder.

  British journal of pharmacology 20181101

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.

  Expert opinion on drug metabolism & toxicology 20130501

• Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

  International journal of clinical pharmacology and therapeutics 20121101

• Use of mirabegron in treating overactive bladder.

  International urogynecology journal 20121001

• Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.

  Xenobiotica; the fate of foreign compounds in biological systems 20121001

• Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

  Clinical therapeutics 20121001

• Emerging therapies: what's new is old and what's old is new.

  The Canadian journal of urology 20121001

• An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120815

• Overactive bladder, under scrutiny, gets a new treatment.

  Nature medicine 20120801

• Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.

  BJU international 20120701

• Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.

  BJU international 20120701

• [Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120501

• Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.

  Postgraduate medicine 20120501

• Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.

  Postgraduate medicine 20120501

• Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.

  Drug metabolism and disposition: the biological fate of chemicals 20120401

• Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301

• Mirabegron for the treatment of overactive bladder.

  Drugs of today (Barcelona, Spain : 1998) 20120101

• Mirabegron: a safety review.

  Expert opinion on drug safety 20110301

• Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder.

  Korean journal of urology 20101201

• Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.

  IDrugs : the investigational drugs journal 20101001

• Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges.

  Naunyn-Schmiedeberg's archives of pharmacology 20100801

• Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder.

  World journal of urology 20091201

• Pharmacotherapy of the overactive bladder.

  Discovery medicine 20091001

• Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.

  European urology 20090701

• Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?

  British journal of pharmacology 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080601

• Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

  The Journal of pharmacology and experimental therapeutics 20070501

• Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines.

  Urology 20070401

• A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.

  The Journal of urology 20030801

• Beta3-adrenoceptors in human detrusor muscle.

  Urology 20020501